Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Benzinga Newsdesk 1 month ago
News
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys 7 to 10 years of age. Forazapadin is an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DMD, facioscapulohumeral muscular dystrophy (FSHD) and potentially other degenerative muscle diseases.